Canada: Ten Significant Changes To Canada's NOC Regulations

On July 15, 2017, the Canadian government published (link) its proposed amendments to the NOC Regulations. These amendments will implement sweeping changes to pharmaceutical patent litigation in Canada pursuant to obligations imposed under CETA. There will be a 15-day comment period, after which, the amendments will be published in final form. The finalized amendments are expected to be in force around late September 2017. These revamped NOC Regulations will apply to Notices of Allegation ("NOAs") served on or after the date the revamped NOC Regulations come into force.

Overall, the revamped NOC Regulations make amendments that were sought after by both sides of the Canadian pharmaceutical industry. For innovators the NOC Regulations provide appeal rights, allow for the early adjudication of additional patent claims and patents not eligble for listing on the Patent Register prior to generic launch, and give effect to patent term restoration. For generics the NOC Regulations limit or prevent follow-on litigation, expand potential section 8 damages and grant expanded standing to sue for impeachment. These and other changes are described in more detail below.

Significant Changes

  1. Actions not Applications: NOC cases will be converted from summary proceedings to actions that determine the validity and infringement of asserted patents. This change will necessitate documentary and oral discovery as well as live witness testimony at trial. NOAs are still required to address all patents listed on the Patent Register. The timelines for commencing a proceeding (45 days) and for the statutory stay (24 months) remain unchanged. The action is limited to a request for a declaration of infringement in respect of any asserted patent. Any patent owner must be made a party to the action, and a counterclaim for a declaration of invalidity may be made in response.
  2. Early disclosure: New early disclosure requirements apply to both second persons (the "Generic") and first persons (the "Innovator"). A Generic's NOA must now be accompanied by electronic documents, in English or French, cited in the invalidity allegations, as well as any portions of the regulatory dossier relevant to the infringement of any patent listed on the Patent Register. Notably, this latter requirement persists even where the Generic has made no allegation of non-infringement. Conversely, if a sufficiently specific request has been made by a Generic and provided with its NOA, the Innovator is subject to fairly onerous disclosure requirements. Contact information for inventors may have to be provided, as well as laboratory notebooks, research reports or other documents in electronic format, in English or French, that may be relevant to determine whether a particular property, advantage, or use asserted to be part of the invention was established as of the filing date of the application for the patent. Such a request must be forwarded to the owner of each patent within 5 days and the Generic must be promptly notified of this being done, or notified that the Innovator is the patent owner. If the Innovator commences an NOC case, these materials must be served on the Generic along with the statement of claim (i.e., within 45 days of receiving the NOA). If they are not yet available, a document explaining the steps that have been and are being taken to locate the information, or setting out the reasons for not providing them, must be served instead. Parties may now impose confidentiality requirements to protect these documents, where appropriate. The Court, on request by a party or on its own initiative, may amend such requirements.
  3. All claims of listed patents can be litigated: Although patent listing requirements remain unchanged, all claims of a listed patent can now be litigated instead of just those claims for the medicinal ingredient, the formulation, the dosage form, or the use of the medicinal ingredient. If it is determined that a patent is not properly listed, the NOC case will no longer be dismissed, but the 24-month stay will not be effective insofar as that patent is concerned.
  4. No repeat patent infringement claims: If a listed patent is the subject of an NOA, and there is a reasonable basis within the 45-day window to sue, then the only action that can be brought in respect of that patent is an NOC case. In such circumstances, the Innovator cannot allow the NOA to pass and sue for infringement at a later date; or, arguably, to defend s. 8 damages claims based on the infringement of addressed patents. Whether the Innovator had a "reasonable basis" to commence an action will be dependent on the quality of the Generic's disclosure provided to the Innovator during the 45-day timeframe.
  5. Court process for timely resolution: The Court has broad powers to manage NOC cases. Any appeal of an interlocutory order must now be brought directly to the Federal Court of Appeal, instead of the Federal Court, and leave is required. The Court is also empowered to shorten or lengthen the 24-month stay and impose costs sanctions if a party fails to act diligently or reasonably cooperate in the action.
  6. More remedies available: The Court is now permitted to order any remedy available under the Patent Act in an NOC case, including damages and injunctions. For example, an injunction could be ordered to prevent ongoing sales of a generic drug in a situation where an NOC was granted before the NOC case was finally determined.
  7. Burden of proof shifted: Any person alleging that a patent is invalid in an NOC case will now bear the burden of proof.
  8. Appeals no longer mooted by NOC grant: Appeals of losses by Innovators in NOC cases will no longer be rendered moot by the grant of a Generic NOC by Health Canada.
  9. Section 8 damages expanded but avoidable: While the right to claim s. 8 damages remain, the NOC Regulations no longer specify an end date to the calculation. This may allow Generics to claim expanded future losses, including claims relating to "double ramp-up" and future market share erosion. While the commencement of an NOC case still triggers an automatic 24-month stay preventing NOC grant, the 24-month stay can be renounced when the action is brought in order to avoid potential liability for s. 8 damages while still preserving the right to sue and obtain any remedy from the Court permitted by the Patent Act.
  10. New separate rights of action: A person who files a copycat drug submission that has reasonable grounds to believe they might be alleged to infringe a patent, now has the right to bring an impeachment action. Furthermore, a person who receives an NOA may now commence a separate patent infringement action in respect of any patents that are not the subject of the NOA without risk of the lawsuit being dismissed as premature. This allows for early litigation over non-listed patents, and dual litigation that can proceed along two tracks. For example, a patentee might bring one fast-tracked lawsuit involving listed patents (that is intended to be completed within 24-months of commencement), along with a separate lawsuit involving non-listed patents, that may or may not be prosecuted as quickly. Such actions must remain separate and cannot be joined while the 24-month stay is extant.

    BONUS

  11. Certificates of Supplementary Protection ("CSP"): The Federal Government released the Certificate of Supplementary Protection Regulations concomitantly with the revamped NOC Regulations. The revamped NOC Regulations include CSP protection, often referred to as "patent term restoration". Innovators may obtain up to two years of additional patent term as a result of delays in the time spent in research and obtaining marketing authorization. Importantly, a CSP can apply to patents and Generics that are already the subject of an action pursuant to the revamped NOC Regulations.

To view the original article click here

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.